Stock Events

Stock Events

Nanobiotix

$9.1

152

-$6.8-42.77% Wednesday 20:47

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

317.37M

P/E Ratio

0

Dividend Yield

-

Dividend

-

Upcoming

Earnings

31MarExpected

Q1 2023

Q2 2023

Q1 2024

Q2 2024

Q1 2025

Q2 2025

Q4 2025

-1.73

-1.05

-0.38

0.3

Expected EPS

0.29950005

Actual EPS

-0.4580589

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NNBXF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotech company that develops innovative therapies, including for cancer, which competes with Nanobiotix's focus on nanomedicine for oncology.

Merck is a global healthcare company that produces cancer treatments, directly competing with Nanobiotix's cancer-focused nanotherapeutics.

Novartis is involved in the research and development of novel healthcare solutions, including cancer treatments, making it a competitor in the oncology space.

Pfizer develops and manufactures drugs and vaccines, including for cancer, competing with Nanobiotix's oncology innovations.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that develops cancer therapies, competing with Nanobiotix's approach to cancer treatment.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company focusing on cancer drugs, competing with Nanobiotix's cancer treatment technologies.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on developing biopharmaceutical treatments, including for cancer, making it a competitor to Nanobiotix.

Vertex Pharmaceuticals

Vertex Pharmaceuticals engages in creating new therapies, including for serious diseases potentially overlapping with Nanobiotix's target areas.

About

Health Technology

Biotechnology

Pharmaceuticals: Major

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Show more...

CEO

Laurent Lévy

Country

FR

ISIN

FR0011341205

WKN

000A1J7EB

Listings

0 Comments

Share your thoughts

FAQ

What is Nanobiotix stock price today?▼

The current price of NNBXF is $9.1 USD — it has decreased by -42.77% in the past 24 hours. Watch Nanobiotix stock price performance more closely on the chart.

What is Nanobiotix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Nanobiotix stocks are traded under the ticker NNBXF.

What is Nanobiotix market cap?▼

Today Nanobiotix has the market capitalization of 317.37M

What were Nanobiotix earnings last quarter?▼

NNBXF earnings for the last quarter are -0.52 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.

In which sector is Nanobiotix located?▼

Nanobiotix operates in the Healthcare sector.

When did Nanobiotix complete a stock split?▼

Nanobiotix has not had any recent stock splits.

Where is Nanobiotix headquartered?▼

Nanobiotix is headquartered in Paris, FR.